It is a startCompletion of Initial Shipment of MiraWell(TM) Rapid HIV Test
2/6/03
MedMira Inc. ('MedMira') announced that its has completed its initial shipment of the MiraWell(TM) Rapid HIV Test to a distributor in the African nation of Tunisia for an order of 60,000 tests.
'The delivery of this shipment to our Tunisia distributor is a significant milestone for our Sales and Marketing team', said Stephen Sham, Chairman and CEO of MedMira. 'We have spent considerable time over the past years building relationships in anticipation of entering the rapid diagnostic product market in the African nations. This contract, while small, has opened the door to the private sector market, positioning MedMira to capture significant market share in the African diagnostic marketplace.'
MedMira is a commercial biotechnology company that develops, manufactures and markets qualitative, in vitro diagnostic tests for the detection of antibodies to certain diseases, such as HIV, in human serum, plasma or whole blood. The most advanced of these products are the Reveal and MiraWell(TM) Rapid HIV tests, believed to be in the final stages of the United States FDA and Chinese SDA regulatory approval process. Other existing products include tests for Hepatitis B, Hepatitis C and combination tests for Hepatitis C/Hepatitis B/HIV. All of MedMira's diagnostic tests are based on the same flow-through technology platform thus facilitating the development of future products. MedMira's technology provides a quick (under 3 minutes), accurate, portable, safe and cost-effective alternative to conventional laboratory testing.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly filings.
CONTACT: TEL: (902) 450-1588 Dr. James Smith
E-mail: ir@medmira.com